CN105307636A - 非晶形特考韦瑞制备 - Google Patents
非晶形特考韦瑞制备 Download PDFInfo
- Publication number
- CN105307636A CN105307636A CN201480026785.8A CN201480026785A CN105307636A CN 105307636 A CN105307636 A CN 105307636A CN 201480026785 A CN201480026785 A CN 201480026785A CN 105307636 A CN105307636 A CN 105307636A
- Authority
- CN
- China
- Prior art keywords
- methods according
- octahydro
- trifluoromethyl
- dioxo
- benzoylamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/72—4,7-Endo-alkylene-iso-indoles
- C07D209/76—4,7-Endo-alkylene-iso-indoles with oxygen atoms in positions 1 and 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010516675.7A CN111635353A (zh) | 2013-07-19 | 2014-07-11 | 非晶形特考韦瑞制备 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361856240P | 2013-07-19 | 2013-07-19 | |
| US61/856,240 | 2013-07-19 | ||
| PCT/US2014/046340 WO2015009566A1 (en) | 2013-07-19 | 2014-07-11 | Amorphous tecovirimat preparation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010516675.7A Division CN111635353A (zh) | 2013-07-19 | 2014-07-11 | 非晶形特考韦瑞制备 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105307636A true CN105307636A (zh) | 2016-02-03 |
Family
ID=52346653
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480026785.8A Pending CN105307636A (zh) | 2013-07-19 | 2014-07-11 | 非晶形特考韦瑞制备 |
| CN202010516675.7A Pending CN111635353A (zh) | 2013-07-19 | 2014-07-11 | 非晶形特考韦瑞制备 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010516675.7A Pending CN111635353A (zh) | 2013-07-19 | 2014-07-11 | 非晶形特考韦瑞制备 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9670158B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3763702B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6843616B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN105307636A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014290333B2 (cg-RX-API-DMAC7.html) |
| CA (3) | CA2917199C (cg-RX-API-DMAC7.html) |
| IL (1) | IL242331B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015009566A1 (cg-RX-API-DMAC7.html) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107126419A (zh) * | 2016-02-26 | 2017-09-05 | 石药集团中诺药业(石家庄)有限公司 | 一种奥贝胆酸片剂及其制备方法 |
| CN115141136A (zh) * | 2021-03-31 | 2022-10-04 | 中国人民解放军军事科学院军事医学研究院 | 特考韦瑞药的共晶及其制备方法 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105307636A (zh) * | 2013-07-19 | 2016-02-03 | 西佳技术公司 | 非晶形特考韦瑞制备 |
| CN112955130A (zh) * | 2018-10-30 | 2021-06-11 | 佩洛通治疗公司 | 包含取代茚满的固体分散体和药物组合物及其制备和使用方法 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010053778A1 (en) * | 2000-03-16 | 2001-12-20 | Hoover Dennis J. | Pharmaceutical compositions of glycogen phosphorylase inhibitors |
| US20070003516A1 (en) * | 2005-04-08 | 2007-01-04 | Almond Merrick R | Compounds, compositions and methods for the treatment of poxvirus infections |
| US20080004452A1 (en) * | 2003-06-20 | 2008-01-03 | Siga Technologies, Inc. | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
| CN102406617A (zh) * | 2011-11-30 | 2012-04-11 | 中国人民解放军军事医学科学院生物工程研究所 | 一种替韦立马干混悬剂及其制备方法 |
| CN103002880A (zh) * | 2010-06-09 | 2013-03-27 | Abbvie公司 | 含有激酶抑制剂的固态分散体 |
| CN103068232A (zh) * | 2010-03-23 | 2013-04-24 | 西佳科技股份有限公司 | 多晶型物形式st-246和制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596771B2 (en) | 2001-01-12 | 2003-07-22 | Schering Corporation | Drugs for treating viral infections |
| US6433016B1 (en) | 2001-01-12 | 2002-08-13 | Vassil Stefanov Georgiev | Drugs for treating viral infections |
| PL1638938T3 (pl) | 2003-06-20 | 2017-10-31 | Siga Tech Inc | Związki, kompozycje i sposoby do leczenia i zapobiegania infekcjom ortopokswirusami i powiązanym chorobom |
| JP2010526848A (ja) * | 2007-05-11 | 2010-08-05 | エフ.ホフマン−ラ ロシュ アーゲー | 難溶性薬物用の医薬組成物 |
| GB201103837D0 (en) * | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
| WO2012122279A1 (en) * | 2011-03-08 | 2012-09-13 | Zalicus Pharmaceuticals Ltd. | Solid dispersion formulations and methods of use thereof |
| KR102000312B1 (ko) * | 2011-10-14 | 2019-07-15 | 어레이 바이오파마 인크. | Erb2 (her2) 저해제의 고체 분산물 |
| JP2013103899A (ja) * | 2011-11-11 | 2013-05-30 | Fuji Chem Ind Co Ltd | 難溶性薬物の新規な固体分散体 |
| CN105307636A (zh) | 2013-07-19 | 2016-02-03 | 西佳技术公司 | 非晶形特考韦瑞制备 |
-
2014
- 2014-07-11 CN CN201480026785.8A patent/CN105307636A/zh active Pending
- 2014-07-11 EP EP20190932.2A patent/EP3763702B1/en active Active
- 2014-07-11 CA CA2917199A patent/CA2917199C/en active Active
- 2014-07-11 AU AU2014290333A patent/AU2014290333B2/en active Active
- 2014-07-11 WO PCT/US2014/046340 patent/WO2015009566A1/en not_active Ceased
- 2014-07-11 CN CN202010516675.7A patent/CN111635353A/zh active Pending
- 2014-07-11 US US14/903,083 patent/US9670158B2/en active Active
- 2014-07-11 CA CA3128535A patent/CA3128535C/en active Active
- 2014-07-11 JP JP2016526997A patent/JP6843616B2/ja active Active
- 2014-07-11 CA CA3246369A patent/CA3246369A1/en active Pending
- 2014-07-11 EP EP14825621.7A patent/EP3021836B1/en active Active
-
2015
- 2015-10-29 IL IL242331A patent/IL242331B/en active IP Right Grant
-
2017
- 2017-04-27 US US15/498,787 patent/US9889119B2/en active Active
-
2018
- 2018-01-02 US US15/860,262 patent/US10045963B2/en active Active
-
2020
- 2020-11-25 JP JP2020195121A patent/JP7681393B2/ja active Active
-
2023
- 2023-04-12 JP JP2023065084A patent/JP2023080234A/ja active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010053778A1 (en) * | 2000-03-16 | 2001-12-20 | Hoover Dennis J. | Pharmaceutical compositions of glycogen phosphorylase inhibitors |
| US20080004452A1 (en) * | 2003-06-20 | 2008-01-03 | Siga Technologies, Inc. | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
| US20070003516A1 (en) * | 2005-04-08 | 2007-01-04 | Almond Merrick R | Compounds, compositions and methods for the treatment of poxvirus infections |
| CN103068232A (zh) * | 2010-03-23 | 2013-04-24 | 西佳科技股份有限公司 | 多晶型物形式st-246和制备方法 |
| CN103002880A (zh) * | 2010-06-09 | 2013-03-27 | Abbvie公司 | 含有激酶抑制剂的固态分散体 |
| CN102406617A (zh) * | 2011-11-30 | 2012-04-11 | 中国人民解放军军事医学科学院生物工程研究所 | 一种替韦立马干混悬剂及其制备方法 |
Non-Patent Citations (6)
| Title |
|---|
| DOUGLAS W GROSENBACH,等: "Development of the small-molecule antiviral ST-246 as a smallpox therapeutic", 《FUTURE VIROLOGY》 * |
| JENS T.CARSTENSEN: "《现代药用粉体微粒学》", 31 October 2004, 中国医药科技出版社 * |
| 潘卫三: "《工业药剂学 第2版》", 31 March 2013, 高等教育出版社 * |
| 罗明生,等: "《药剂辅料大全》", 31 January 2006, 四川出版集团·四川科学技术出版社 * |
| 罗杰英,等: "《现代物理药剂学理论与实践》", 31 May 2007, 上海科学技术文献出版社 * |
| 董铭心,等: "替韦立马一水合物的制备及新晶型结构测定", 《中国新药杂志》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107126419A (zh) * | 2016-02-26 | 2017-09-05 | 石药集团中诺药业(石家庄)有限公司 | 一种奥贝胆酸片剂及其制备方法 |
| CN107126419B (zh) * | 2016-02-26 | 2020-06-19 | 石药集团中诺药业(石家庄)有限公司 | 一种奥贝胆酸片剂及其制备方法 |
| CN115141136A (zh) * | 2021-03-31 | 2022-10-04 | 中国人民解放军军事科学院军事医学研究院 | 特考韦瑞药的共晶及其制备方法 |
| CN115141136B (zh) * | 2021-03-31 | 2023-06-20 | 中国人民解放军军事科学院军事医学研究院 | 特考韦瑞药的共晶及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3246369A1 (en) | 2025-10-30 |
| IL242331B (en) | 2021-02-28 |
| EP3763702A1 (en) | 2021-01-13 |
| US9670158B2 (en) | 2017-06-06 |
| EP3021836A4 (en) | 2016-12-07 |
| CA2917199C (en) | 2021-08-31 |
| CA2917199A1 (en) | 2015-01-22 |
| EP3021836A1 (en) | 2016-05-25 |
| WO2015009566A1 (en) | 2015-01-22 |
| JP2016527229A (ja) | 2016-09-08 |
| JP2023080234A (ja) | 2023-06-08 |
| JP2021028336A (ja) | 2021-02-25 |
| US10045963B2 (en) | 2018-08-14 |
| US20160152565A1 (en) | 2016-06-02 |
| AU2014290333B2 (en) | 2018-11-08 |
| US20170224661A1 (en) | 2017-08-10 |
| WO2015009566A8 (en) | 2015-12-10 |
| JP6843616B2 (ja) | 2021-03-17 |
| JP7681393B2 (ja) | 2025-05-22 |
| EP3763702B1 (en) | 2023-12-13 |
| US20180125819A1 (en) | 2018-05-10 |
| EP3021836B1 (en) | 2020-10-07 |
| AU2014290333A1 (en) | 2015-12-03 |
| CN111635353A (zh) | 2020-09-08 |
| CA3128535C (en) | 2024-10-15 |
| US9889119B2 (en) | 2018-02-13 |
| CA3128535A1 (en) | 2015-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7681393B2 (ja) | アモルファステコビリマット調製 | |
| US8802714B2 (en) | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases | |
| US20080004452A1 (en) | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | |
| CN104758281A (zh) | 用于治疗和预防正痘病毒感染和相关疾病的化合物、组合物和方法 | |
| EP2192901A2 (en) | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | |
| JP6564514B2 (ja) | テコビリマットの調製方法 | |
| Wang et al. | Discovery and development of VV116: a novel oral nucleoside anti‐SARS‐CoV‐2 drug | |
| AU2012268859B2 (en) | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | |
| CN109651253B (zh) | 苯丙烯酸酯衍生物及其作为神经保护药物的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160203 |
|
| RJ01 | Rejection of invention patent application after publication |